ePrescribing Infrastructure and Impact on the Healthcare Markets in the US and EU

Introduction

Technology has been used to either inform or expedite the prescribing process in most modern healthcare systems for over two decades. Recently, market forces - including greater regulatory intervention, increased investment from stakeholders and decreased resistance from end-users - have begun to converge to set the stage for widespread adoption of truly integrated ePrescribing solutions.

Scope of this report

Insight into the different approaches taken towards adoption of ePrescribing in the US and the EU

Identification of current drivers of adoption and why they are important to the success of ePrescribing long-term

Analysis of physicians' and consumers' views on ePrescribing and how they are affecting the rate of adoption in the US and EU

Recommendations for pharmaceutical industry as to how to retain a share-of-voice in adoption, particularly as regards designing functional standards

Research and analysis highlights

One of the greatest challenges facing ePrescribing has been finding a balance between the wants and needs of industry and end-users. Several stakeholders have been vying for influence over the design and implementation of ePrescribing systems. While this has served to move the market forward considerable conflicts of interest have also emerged.

The attitude of the physician towards ePrescribing is the most important consideration for stakeholders because it is the point at which adoption either stalls or moves forward. Historically, physicians have been offered a variety of reasons and incentives to adopt ePrescribing, with varying degrees of success.

It is the pharmaceutical industry's responsibility to ensure that decisions made at the point of care are not unduly controlled by other stakeholders, such as disruptive messaging meant to influence a physician to continuously second-guess specific prescribing decisions, or inequitable screen displays, which give preference to certain treatments.

Key reasons to read this report

Identify the dangers of the traditional paper-based prescribing model and how electronic prescribing can improve patient safety and compliance

Understand the importance of developing electronic medical records in parallel with ePrescribing initiatives

Assess opportunities for pharmaceutical companies to maintain a share-of-voice during the prescribing process

Published: 20 March 2007

PDF Format
Table of Contents
Price: $3,800.00 / GBP1,976.00